ArticleMolecular cancer therapeutics2024
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.
Abstract readConsensus Statement
In one paragraph
Article in Molecular cancer therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Tumor-on-chip as a personalized platform for rapid drug testing in breast cancer.Cell reports. Medicine · 2026Article
- Bridging tumor growth dynamics and survival in preclinical oncology drug development - a Tumor Growth Inhibition and Time-to-Event (TGI-TTE) modeling framework.Cancer chemotherapy and pharmacology · 2026Article
- Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma.Nature communications · 2026Article
- Bridging Tumor Growth Dynamics and Survival in Preclinical Oncology Drug Development - A Translational Tumor Growth Inhibition and Time to Event (TGI-TTE) Modeling Framework.Research square · 2026Article
- Variable cellular and radiobiological effects of [Journal of experimental & clinical cancer research : CR · 2026Article
- A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma.Cell reports · 2025Article
- Advances and Challenges in Drug Screening for Cancer Therapy: A Comprehensive Review.Bioengineering (Basel, Switzerland) · 2025Review
- Current State-of-the-Art Animal Models of Pediatric Brain Tumors.Brain sciences · 2025Review
- Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations.Molecular cancer therapeutics · 2025Article
- Acquired resistance in cancer: towards targeted therapeutic strategies.Nature reviews. Cancer · 2025Review
- PDX models for functional precision oncology and discovery science.Nature reviews. Cancer · 2025Review
- Opportunities and challenges for patient-derived models of brain tumors in functional precision medicine.NPJ precision oncology · 2025Review
- Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses.bioRxiv : the preprint server for biology · 2025Article
- A precision oncology-focused deep learning framework for personalized selection of cancer therapy.bioRxiv : the preprint server for biology · 2024Article
- XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients.Nature communications · 2024Article
- Building Equitable Cancer Research Infrastructure: Successful Transfer of Patient-Derived Xenograft Technology to a Historically Black University.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funda Meric-BernstamDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-6816-6072
Michael W LloydThe Jackson Laboratory, Bar Harbor, Maine.ORCID 0000-0003-1021-8129
Soner KocSeven Bridges Genomics, Charlestown, Massachusetts.ORCID 0000-0002-0772-6600
Yvonne A EvrardLeidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0002-3475-4850
Lisa M McShaneBiometric Research Program, DCTD, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-8195-3206
Michael T LewisDepartments of Molecular and Cellular Biology and Radiology, Lester and Sue Smith Breast Center, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-6330-4007
Kurt W EvansDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0008-6823-6809
Dali LiDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0002-0418-5797
Lawrence RubinsteinBiometric Research Program, DCTD, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-9720-9737
Alana WelmHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-1412-1351
Dennis A DeanSeven Bridges Genomics, Charlestown, Massachusetts.ORCID 0000-0002-7621-9717
Anuj SrivastavaThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.ORCID 0000-0002-8455-3993
Jeffrey W GroverSeven Bridges Genomics, Charlestown, Massachusetts.ORCID 0000-0001-6246-1767
Min J HaDepartment of Biostatistics, Graduate School of Public Health, Yonsei University, Seoul, Republic of Korea.ORCID 0000-0002-5165-1642
Huiqin ChenDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-2477-5436
Xuelin HuangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1192-9336
Kaushik VaradarajanDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4114-5498
Jing WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5398-0802
Jack A RothDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8955-1313
Bryan WelmHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-1879-6612
Ramaswamy GovindenDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-6964-9612
Li DingDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0003-1517-2975
Salma KaocharDepartment of Medicine, Baylor College of Medicine, Houston, Texas.ORCID 0000-0001-9437-8829
Nicholas MitsiadesDepartment of Molecular Cellular Biology, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-4659-476X
Luis Carvajal-CarmonaDepartment of Biochemistry and Molecular Medicine, University of California, Davis, California.ORCID 0000-0001-7129-2918
Meenhard HerylynThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0003-0839-0739
Michael A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0977-0912
Geoffrey I ShapiroDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-3331-4095
Ryan FieldsDepartment of Surgery, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0001-6176-8943
Jose G TrevinoDepartment of Surgery, Virginia Commonwealth University, Richmond, Virginia.ORCID 0000-0002-0265-8151
Joshua C HarrellDepartment of Pathology, Virginia Commonwealth University, Richmond, Virginia.ORCID 0000-0003-3541-8418
NCI PDXNet Consortium
James H DoroshowDivision of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-4463-1790
Jeffrey H ChuangThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.ORCID 0000-0002-3298-2358
Jeffrey A MoscowInvestigational Drug Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-0479-1693
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9MConvalescent Plasma to Limit Coronavirus Associated ComplicationsUL1TR003167 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KARP, DANIEL D, MCPHERSON, DAVID D · 2019 to 2023
$45.3MTexas EXperimental Cancer Therapeutics Network - TEX CTNUM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos · 2014 to 2026
$20.4MResearch Project 2 - Targeting Melanoma Tumor Survival and Apoptotic MachineryU54CA224070 · NCI · WISTAR INSTITUTE · PI Jessie Villanueva · 2017 to 2026
$13.9MTolinapant efficacy in a subset of triple negative breast cancersU54CA224076 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Michael T. Lewis · 2017 to 2026
$13.5MWashington University PDX Development and Trial Center - Evaluation of Abemaciclib in Combination with Olaparib in Ovarian Cancer and Breast Cancer Patient-derived Xenograft ModelsU54CA224083 · NCI · WASHINGTON UNIVERSITY · PI Brian Andrew Van Tine · 2017 to 2026
$13.0MPDXNet Data Commons and Coordinating CenterU24CA224067 · NCI · JACKSON LABORATORY · PI Jeffrey Hsu-Min Chuang · 2017 to 2026
$9.8MPhase 01 Clinical TrialsZIABC011078 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI DOROSHOW, JAMES · 2009 to 2025
$9.0MUniversity of Texas PDX Development and Trial CenterU54CA224065 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ROTH, JACK · 2017 to 2022
$7.7MUnited for Health Excellence - Living PDX Program (U4HELPP)U54CA283762 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Joshua (Chuck) Harrell, Jose G. Trevino · 2023 to 2026
$5.0MNCATS NIH HHS UL1 TR003167NCI NIH HHS P30 CA010815NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA125123NCI NIH HHS U24 CA224067NCI NIH HHS U54 CA224065NCI NIH HHS U54 CA224070NCI NIH HHS U54 CA224076NCI NIH HHS U54 CA224083NCI NIH HHS UM1 CA186688
Abstract
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.
Indexed as
NeoplasmsXenograft Model Antitumor AssaysAnimalsAntineoplastic AgentsHumansMiceNational Cancer Institute (U.S.)United StatesAntineoplastic Agents
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.